Navigation Links
Avid Bioservices Presents Data From Manufacturing Successes Achieved With Single-Use Bioreactor Systems
Date:2/13/2009

TUSTIN and SAN DIEGO, Calif., Feb. 13 /PRNewswire-FirstCall/ -- Avid Bioservices, Inc. today reported that it presented data from several antibody projects using the company's recently installed Single-Use Bioreactors (S.U.B.) at the Thermo Scientific BioProduction Optimization Workshop held this week in San Diego, California. In response to growing demand for its cGMP bioproduction services, Avid installed a HyClone 1000 L S.U.B. in its manufacturing suite in November 2008, complementing the HyClone 100 L S.U.B. that was already installed in Avid's Process Development unit at its production facilities in Tustin, California.

At the workshop, Avid researchers discussed their early successes using the 100 L S.U.B. and 1000 L S.U.B. systems. Avid senior vice president of bioprocess development and manufacturing Richard Richieri presented data on cell culture performance at both the 100 L and 1000 L scale, demonstrating that the process is scalable and that cell growth and production are very similar in the two systems. Avid's initial analysis of the antibody product also shows excellent comparability between these disposable units and traditional reactors.

"We installed our HyClone S.U.B. systems to help meet the rising demand for our biomanufacturing services," said Mr. Richieri. "Our experience to date with these systems has been very positive, and we welcomed the opportunity to share our insights at this workshop with other industry representatives. Avid's commitment to efficient production has led us to innovate in a number of areas, including installing our two HyClone S.U.B. systems and acquiring a ClonePix automated system for optimal clone selection. These new technologies have been very successful in reducing our processing costs and shortening project timelines."

The Thermo Scientific HyClone S.U.B. consists of a reusable stainless steel outer support container and S.U.B. BioProcess Container (BPC(R)) that integrates with existing bioreactor control systems, providing the advantages of single-use bioprocessing without having to install a complete new bioreactor system. The retrofit product replaces the stainless steel bioreactor vessel in existing bioreactor systems, making it a flexible, rapid and economic option to increase bioreactor capacity.

Avid Bioservices is a wholly owned subsidiary of Peregrine Pharmaceuticals Inc. (Nasdaq: PPHM).

About Avid Bioservices

Avid Bioservices provides a comprehensive range of cGMP manufacturing services for the biotechnology and biopharmaceutical industries. Avid manufactures cGMP commercial product, as well as clinical supplies for all phases of clinical trials. The company's comprehensive range of cGMP services includes cell banking, stability testing, clinical product manufacturing and purification, bulk packaging, final product filling and regulatory support. Avid also provides a variety of process development activities, including cell line optimization, analytical method development and product characterization. The company has over 10 years of antibody manufacturing experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes. Avid was recently named the first pre-approved U.S. contract manufacturer of the DSM/Crucell PER.C6(R) production system. For more information about Avid, visit www.avidbio.com.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus (HCV) infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc., which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

     Contacts:
     Avid Bioservices           Media
     Candice Fliedner           GendeLLindheim BioCom Partners
     (714) 508-6188             Barbara Lindheim
                                (212) 918-4650

'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Avid Bioservices Expands Capabilities With Installation of Innovative Thermo Scientific HyClone Single-Use Bioreactor Systems
2. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
3. ExL Pharma Presents The Pharmaceutical Managed Markets Insight & Marketing for the Pharmaceutical Industry Conference
4. ImQuest Presents IND-Enabling Safety Pharmacology and Pharmacokinetic Data for the Therapeutic HIV Compound IQP-0410 at Conference on Retroviruses and Opportunistic Infections
5. AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences
6. The EntreTech Forum Presents... Greening Of America - The Conversion of Bio-Agriculture, Bio-Energy, and Bio-Products to Eco-Sustainable Businesses
7. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
8. ImmunoVaccine Technologies Presents at OneMed Place Finance Forum
9. Medivation Presents New Data on Dimebons Novel Mechanism of Action
10. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
11. Frost & Sullivan Presents CorMatrix Cardiovascular Inc. with 2008 Healthcare Innovation Award for the Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
Breaking Biology News(10 mins):